https://hvivo.com/wp-content/uploads/2019/09/ERS-presentation-template-Madrid-2019-FINAL-30.09.19.pdf
https://hvivo.com/wp-content/uploads/2019/09/ERS-2019-Ghebre-et-al-25.09.19-FINAL.pdf
https://hvivo.com/wp-content/uploads/2019/10/190831-OptionsX-Pre-existing-NP-T-cell-response-in-HCS-vf.pdf
https://hvivo.com/wp-content/uploads/2019/10/hVIVO_ISIRV-Options-2019_Meta-analysis-H3N2-Perth.pdf
ISIRV Options X Conference, August 28 – September 01, 2019, SUNTEC Singapore, Asia hVIVO is pleased to announce that one... View Article
WVC 2017, 14-17 April 2019, Renaissance Washington DC Downtown Hotel, Washington DC, USA hVIVO is proud to once again be... View Article
Influenza Vaccines For The World 2019, April 02 – 04, Edinburgh, Scotland. hVIVO and its joint venture, Imutex Limited, will... View Article
ISRIV 1st Influenza Vaccine Group Meeting, March 31st – April 2nd, Siena, Italy Alex Man, hVIVO’s Director Clinical Science R&D Operations,... View Article
hVIVO made 4 separate poster presentations at each ISIRV RSV (Asheville, NC USA) and ISIRV AVG (Washington, DC USA) October 2018.... View Article